Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications

Abstract

Background The leading emerging markets of Brazil, Russia, India, China and South Africa (BRICS) are increasingly shaping the landscape of the global health sector demand and supply for medical goods and services. BRICS’ share of global health spending and future projections will play a prominent role during the 2020s. The purpose of the current research was to examine the decades-long underlying historical trends in BRICS countries’ health spending and explore these data as the grounds for reliable forecasting of their health expenditures up to 2030. Methods BRICS’ health spending data spanning 1995–2017 were extracted from the Institute for Health Metrics and Evaluation (IHME) Financing Global Health 2019 database. Total health expenditure, government, prepaid private and out-of-pocket spending per capita and gross domestic product (GDP) share of total health spending were forecasted for 2018–2030. Autoregressive integrated moving average (ARIMA) models were used to obtain future projections based on time series analysis. Results Per capita health spending in 2030 is projected to be as follows: Brazil, $1767 (95% prediction interval [PI] 1615, 1977); Russia, $1933 (95% PI 1549, 2317); India, $468 (95% PI 400.4, 535); China, $1707 (95% PI 1079, 2334); South Africa, $1379 (95% PI 755, 2004). Health spending as a percentage of GDP in 2030 is projected as follows: Brazil, 8.4% (95% PI 7.5, 9.4); Russia, 5.2% (95% PI 4.5, 5.9); India, 3.5% (95% PI 2.9%, 4.1%); China, 5.9% (95% PI 4.9, 7.0); South Africa, 10.4% (95% PI 5.5, 15.3). Conclusions All BRICS countries show a long-term trend towards increasing their per capita spending in terms of purchasing power parity (PPP). India and Russia are highly likely to maintain stable total health spending as a percentage of GDP until 2030. China, as a major driver of global economic growth, will be able to significantly expand its investment in the health sector across an array of indicators. Brazil is the only large nation whose health expenditure as a percentage of GDP is about to contract substantially during the third decade of the twenty-first century. The steepest curve of increased per capita spending until 2030 seems to be attributable to India, while Russia should achieve the highest values in absolute terms. Health policy implications of long-term trends in health spending indicate the need for health technology assessment dissemination among the BRICS ministries of health and national health insurance funds. Matters of cost-effective allocation of limited resources will remain a core challenge in 2030 as well.

How to balance valuable innovation with affordable access to medicines in Belgium?

“…For example, the European Commission's "Pharmaceutical Strategy for Europe" aims, amongst other things, to support investment in R&D of innovative medicines and to promote competition in the off-patent medicines market (European Commission, 2020). Emerging markets such as Brazil, China, India, Indonesia, Mexico, Russia, South Africa and Turkey will face the same challenge as pharmaceutical (and medical device) R&D and innovation is increasingly taking place in these countries, while the demand of their populations for health care is growing (Jakovljevic et al, 2017;Jakovljevic et al, 2021;Jakovljevic et al, 2022a;Jakovljevic et al, 2022b;Sapkota et al, 2022). At global level, an analysis of medicine expenditure in a representative sample of 11 countries showed that spending growth as a result of innovation in oncology and immunology has been offset by savings and increased patient access due to the market entry of generic and biosimilar medicines (Aitken et al, 2021).…”

Correction to: Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications

“…The publisher apologizes to the readers and authors for the inconvenience caused. The original article [ 1 ] has been updated.…”

Environmental Pollution Liability Insurance of Health Risk and Corporate Environmental Performance: Evidence From China

“…This is increasingly becoming one of the top priorities in governing authority's agendas ( 3 , 4 ). It is clearly documented with a bold rise in Chinese domestic health and pharmaceutical spending in medium-term forecasted projections up to 2025 ( 5 ) and 2030 ( 6 ). The responsibility frontier in policy makers' mindset is now shifting from the public sector toward the private-owned manufacturing industry ( 7 ).…”